工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Engineered macrophages accumulate in solid tumors and locally deliver immune-activating proteins to inhibit tumor progression.
Engineered macrophages accumulate in solid tumors and locally deliver immune-activating proteins to inhibit tumor progression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究显示了 GEMs 在肿瘤治疗中的潜在临床应用。
目前,免疫检查点抑制剂(ICIs)和其他免疫激活策略是癌症治疗的主要方法;然而,许多实体瘤中的免疫抵抗限制了免疫治疗反应,并可能导致强烈的毒性副作用。在实体瘤中,有效的抗肿瘤免疫反应的发展受到免疫细胞浸润有限和免疫抑制性肿瘤微环境(TME)的阻碍。为了克服当前的免疫治疗挑战,我们提出了一种新方法,提供局部和稳定的治疗水平以激活或重振抗肿瘤免疫,从而实现TME浸润和在实体瘤中持续存在的效果。
利用基因工程方法协同激活TME中的免疫,我们将巨噬细胞编程为表达治疗性有效载荷,包括白细胞介素(IL)-12和信号调节蛋白α-可结晶片段融合蛋白(SIRPα-Fc),一种CD47 ICI。进行了共培养研究,以评估基因工程巨噬细胞(GEMs)在体外对T细胞和GEMs本身的影响。我们评估了肿瘤反应、细胞反应和细胞因子反应。将GEMs给予肿瘤细胞移植小鼠模型,在其中它们被保留并作为慢病毒有效载荷表达。
GEMs分泌的IL-12为T细胞提供了效应信号,从而增强了肿瘤驻留的抗肿瘤巨噬细胞和CD8+ T细胞群体。此外,SIRPα-Fc的分泌增强了巨噬细胞对肿瘤细胞的吞噬活性,并促进了其抗原呈递功能。双蛋白联合治疗在实体瘤模型中产生了显著的协同效应,并进一步增强了记忆免疫。GEMs还提高了ICIs在ICI耐药基因工程肿瘤模型中的疗效,并在转移模型中展示了显著的抗肿瘤效果。
Currently, immune checkpoint inhibitors (ICIs) and other immune-activating strategies represent the main approach to cancer treatment; however, immune resistance in many solid tumors limits the immune therapy response and can cause strong toxic side effects. In solid tumors, the development of effective anti-tumor immune responses is hindered by limited immune cell infiltration and an immunosuppressive tumor microenvironment (TME). To overcome current immunotherapy challenges, we proposed a novel approach providing local and stable treatment levels to activate or revitalize anti-tumor immunity, to achieve the effect of TME infiltration and sustained presence in solid tumors.
Using genetic engineering methods to synergistically activate immunity in the TME, we programmed macrophages to express therapeutic payloads, including interleukin (IL)-12 and the signal regulatory protein alpha-Fragment crystallizable fusion protein (SIRPα-Fc), a CD47 ICI. Co-culture studies were performed to evaluate the effects of the genetically engineered macrophages (GEMs) on the T cells and GEMs themselves in vitro . We evaluated the tumor response, cellular response, and cytokine response. The GEMs were administered to a mouse model of tumor-cell transplantation, where they were retained and expressed as lentiviral payloads.
The IL-12 secreted by the GEMs provided effector signals for T cells, thereby enhancing the tumor resident anti-tumor macrophages and CD8 + T-cell populations. In addition, the secretion of SIRPα-Fc enhanced the phagocytic activity of the macrophages toward tumor cells and promoted their antigen presentation function. The combination therapy of dual proteins produced significant synergistic effects in solid tumor models and further enhanced memory immunity. The GEMs also improved the efficacy of ICIs in the ICI-resistant gene engineering tumor models and demonstrated significant anti-tumor efficacy in the metastasis models.
Our study showed the potential clinical application of GEMs in the treatment of tumors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。